BR112014016635A2 - composto, composição, e, uso de um composto - Google Patents
composto, composição, e, uso de um compostoInfo
- Publication number
- BR112014016635A2 BR112014016635A2 BR112014016635A BR112014016635A BR112014016635A2 BR 112014016635 A2 BR112014016635 A2 BR 112014016635A2 BR 112014016635 A BR112014016635 A BR 112014016635A BR 112014016635 A BR112014016635 A BR 112014016635A BR 112014016635 A2 BR112014016635 A2 BR 112014016635A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN20120011031.8 | 2012-01-13 | ||
| CN201210011031 | 2012-01-13 | ||
| CN201210573072.6 | 2012-12-25 | ||
| CN201210573072.6A CN103204838B (zh) | 2012-01-13 | 2012-12-25 | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 |
| PCT/CN2012/088016 WO2013104263A1 (zh) | 2012-01-13 | 2012-12-31 | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR112014016635A2 true BR112014016635A2 (pt) | 2017-06-13 |
| BR112014016635A8 BR112014016635A8 (pt) | 2017-07-04 |
| BR112014016635B1 BR112014016635B1 (pt) | 2021-07-13 |
| BR112014016635B8 BR112014016635B8 (pt) | 2021-08-24 |
Family
ID=48752268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014016635A BR112014016635B8 (pt) | 2012-01-13 | 2012-12-31 | composto, composição, e, uso de um composto |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9221781B2 (pt) |
| EP (1) | EP2803665B1 (pt) |
| JP (1) | JP6113751B2 (pt) |
| KR (1) | KR102030207B1 (pt) |
| CN (1) | CN103204838B (pt) |
| AU (1) | AU2012365712B2 (pt) |
| BR (1) | BR112014016635B8 (pt) |
| CA (1) | CA2860999C (pt) |
| ES (1) | ES2627316T3 (pt) |
| MX (1) | MX364833B (pt) |
| WO (1) | WO2013104263A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101784990B1 (ko) * | 2016-01-13 | 2017-10-12 | 주식회사 파이브지티 | 얼굴인식을 이용한 홈 오토메이션 제어 시스템 및 그 방법 |
| CN107163014B (zh) * | 2016-07-15 | 2019-10-15 | 北京盛诺基医药科技有限公司 | 一种淫羊藿素的合成方法 |
| CN107298667B (zh) * | 2016-07-15 | 2020-09-08 | 北京盛诺基医药科技股份有限公司 | 淫羊藿素的合成方法 |
| ES2895965T3 (es) * | 2016-08-16 | 2022-02-23 | Uwm Res Foundation Inc | Moduladores del receptor de GABA(A) y métodos para controlar la hiperreactividad de las vías respiratorias y la inflamación en el asma |
| US10266510B2 (en) | 2017-01-18 | 2019-04-23 | King Abdulaziz University | Antimicrobial and cytotoxic compounds and methods for treating cancer, a bacterial infection, and/or a fungal infection |
| CN108947949B (zh) * | 2017-05-19 | 2022-08-19 | 泰州华元医药科技有限公司 | 抗焦虑氘代化合物及其医药用途 |
| CN109020938A (zh) * | 2018-08-17 | 2018-12-18 | 昆明龙津药业股份有限公司 | 一种杨梅素的制备方法 |
| CN110054605A (zh) * | 2019-05-31 | 2019-07-26 | 北京盛诺基医药科技有限公司 | 一种淫羊藿素中间体的制备方法 |
| CN110092770A (zh) * | 2019-05-31 | 2019-08-06 | 北京盛诺基医药科技有限公司 | 一种黄酮化合物中间体的制备方法 |
| CN112569222A (zh) * | 2020-12-31 | 2021-03-30 | 赣南医学院 | 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用 |
| CN112851615B (zh) * | 2021-01-21 | 2023-04-07 | 厦门大学 | 一种异戊烯基黄酮的制备及其作为治疗宫颈癌药物的应用 |
| CN113717138B (zh) * | 2021-10-21 | 2023-02-24 | 沈阳药科大学 | 一类氮芥类色原酮衍生物与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1786864A (zh) | 2004-12-10 | 2006-06-14 | 上海迪比特实业有限公司 | 一种计算机安全认证方法 |
| JP2007332695A (ja) | 2006-06-16 | 2007-12-27 | Advanced Media Inc | 電子錠装置及び音声認証ロッカーシステム |
| WO2008100977A2 (en) * | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| CN101104611A (zh) * | 2007-04-29 | 2008-01-16 | 殷正丰 | 一种3-甲氧基黄酮类化合物,其制备方法和应用 |
| WO2009129372A1 (en) * | 2008-04-18 | 2009-10-22 | Shenogen Pharma Group Ltd. | Compounds and methods for treating estrogen receptor-related diseases |
| CN102038673B (zh) | 2009-10-20 | 2012-07-25 | 北京珅奥基医药科技有限公司 | 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用 |
| CN102558164B (zh) | 2010-12-31 | 2016-06-15 | 北京盛诺基医药科技有限公司 | 苯并吡喃酮类雌激素受体调节剂 |
-
2012
- 2012-12-25 CN CN201210573072.6A patent/CN103204838B/zh active Active
- 2012-12-31 WO PCT/CN2012/088016 patent/WO2013104263A1/zh active Application Filing
- 2012-12-31 AU AU2012365712A patent/AU2012365712B2/en active Active
- 2012-12-31 KR KR1020147022558A patent/KR102030207B1/ko active IP Right Grant
- 2012-12-31 CA CA2860999A patent/CA2860999C/en active Active
- 2012-12-31 MX MX2014008526A patent/MX364833B/es active IP Right Grant
- 2012-12-31 JP JP2014551506A patent/JP6113751B2/ja active Active
- 2012-12-31 BR BR112014016635A patent/BR112014016635B8/pt active IP Right Grant
- 2012-12-31 ES ES12864757.5T patent/ES2627316T3/es active Active
- 2012-12-31 EP EP12864757.5A patent/EP2803665B1/en active Active
- 2012-12-31 US US14/371,866 patent/US9221781B2/en active Active - Reinstated
Also Published As
| Publication number | Publication date |
|---|---|
| ES2627316T3 (es) | 2017-07-27 |
| AU2012365712A1 (en) | 2014-07-24 |
| CA2860999A1 (en) | 2013-07-18 |
| MX2014008526A (es) | 2014-11-25 |
| WO2013104263A1 (zh) | 2013-07-18 |
| CN103204838B (zh) | 2017-06-09 |
| JP6113751B2 (ja) | 2017-04-12 |
| CA2860999C (en) | 2019-12-31 |
| EP2803665B1 (en) | 2017-05-10 |
| JP2015503596A (ja) | 2015-02-02 |
| KR20140109498A (ko) | 2014-09-15 |
| KR102030207B1 (ko) | 2019-10-08 |
| BR112014016635B1 (pt) | 2021-07-13 |
| EP2803665A1 (en) | 2014-11-19 |
| CN103204838A (zh) | 2013-07-17 |
| AU2012365712B2 (en) | 2017-04-20 |
| BR112014016635B8 (pt) | 2021-08-24 |
| US20150011618A1 (en) | 2015-01-08 |
| BR112014016635A8 (pt) | 2017-07-04 |
| MX364833B (es) | 2019-05-08 |
| EP2803665A4 (en) | 2015-07-08 |
| US9221781B2 (en) | 2015-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| BR112014000260A2 (pt) | composto, e, uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014016635A8 (pt) | composto, composição, e, uso de um composto | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| BR112016003229A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| BR112014023200A2 (pt) | uso de uma composição | |
| BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112014032798A2 (pt) | composição | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112013029206A2 (pt) | composto, e, uso de um composto | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112014029642A2 (pt) | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014009471A2 (pt) | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/12/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2636 DE 13/07/2021 QUANTO AO PRIORIDADE UNIONISTA. |